Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors

Cancer Causes and Control

Volumn 24, Issue 7, 2013, Pages 1459-1464

  Rasmussen, Christina B ^a   Faber, Mette T ^a   Jensen, Allan ^a   Høgdall, Estrid ^a,b   Høgdall, Claus ^c   Blaakær, Jan ^d   Kjaer, Susanne K ^a,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Inflammation; Ovarian borderline tumor; Ovarian cancer; Pelvic inflammatory disease; Risk factor

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; OVARY BORDERLINE TUMOR; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PELVIC INFLAMMATORY DISEASE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SELF REPORT; TUMOR INVASION;

ADULT; AGED; CASE-CONTROL STUDIES; DENMARK; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; RISK FACTORS;

EID: 84878938651     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0216-y     Document Type: Article

References (22)

1. Fathalla MF (1971) Incessant ovulation - a factor in ovarian neoplasia? Lancet 2:163
2. Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717-721 (Pubitemid 14232385)
3. Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459-1467 (Pubitemid 29424550)
4. Shan W, Liu J (2009) Inflammation: A hidden path to breaking the spell of ovarian cancer. Cell Cycle 8:3107-3111
5. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98:1781-1783 (Pubitemid 351748854)
6. Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, et al. (2013) Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 92:245-255
7. Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, et al. (2011) Risk of ovarian cancer in women with pelvic inflammatory disease: A population-based study. Lancet Oncol 12:900-904
8. Lareau SM, Beigi RH (2008) Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin North Am 22:693-708, vii
9. Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih I (2011) Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 35:1605-1614
10. Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19:58-64
11. Seidman JD, Sherman ME, Bell KA, Katabuchi H, O'Leary TJ, Kurman RJ (2002) Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection? Int J Gynecol Pathol 21:101-107 (Pubitemid 34260629)
12. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al. (2000) Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:111-117 (Pubitemid 30112009)
13. Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L (1996) Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 5:667-669 (Pubitemid 26294976)
14. Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4:447-451
15. Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 49:3670-3674 (Pubitemid 19178194)
16. Merritt MA, Green AC, Nagle CM, Webb PM (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170-176 (Pubitemid 350209992)
17. Huusom LD, Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK, et al. (2006) Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: A Danish case-control study. Cancer Causes Control 17:821-829
18. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, et al. (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16:1160-1166 (Pubitemid 46984953)
19. Crispens MA (2003) Borderline ovarian tumours: A review of the recent literature. Curr Opin Obstet Gynecol 15:39-43 (Pubitemid 36143491)
20. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 83:575-585 (Pubitemid 33139723)
21. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218-224 (Pubitemid 40170640)
22. Aral SO, Mosher WD, Cates W Jr (1985) Self-reported pelvic inflammatory disease in the US: A common occurrence. Am J Public Health 75:1216-1218 (Pubitemid 15013123)